The Business Case for AI with Novartis and Gartner
In this webinar, experts from Gartner and Novartis join the Causaly team to share their insights into the latest AI technologies transforming life sciences, and how to put those AI tools to work in real world pharma use cases.
Watch this gripping session from experts at Novartis and Gartner as they discuss the increased adoption of AI in the life sciences industry and, in particular, the impact of AI on R&D processes.
AI is rapidly redefining how life sciences organizations approach R&D. As data volumes grow exponentially and precision medicine becomes the norm, traditional research methods can no longer keep pace. In this exclusive webinar, Gartner unveils its latest research “Hype Cycle for Life Sciences R&D, 2025,” highlighting transformative technologies including AI, with a particular focus on Agentic AI, that are critical for staying competitive. You'll also hear how Novartis is applying AI to real-world discovery workflows, and how Causaly’s AI platform enables faster, evidence-based decisions in research processes.
Featured Speakers:
🔹 Reuben Harwood - Director Analyst, Life Sciences, Gartner
🔹 Jeremy Jenkins - US Head of Discovery, Novartis
🔹 Janis Tam - Science Liaison, Team Lead, Causaly
About the speakers
Get to know Causaly
What would you ask the team behind life sciences’ most advanced AI? Request a demo and get to know Causaly.
Request a demo